Welcome to our dedicated page for Curaleaf Hldgs news (Ticker: CURLF), a resource for investors and traders seeking the latest updates and insights on Curaleaf Hldgs stock.
Curaleaf Holdings, Inc. reports developments across its consumer cannabis business, including retail dispensary openings, medical and adult-use product brands, quarterly operating results, and international expansion. The company trades on the Toronto Stock Exchange as CURA and on OTCQX as CURLF.
Recurring updates cover brands such as Curaleaf, Select, Grassroots, Find, Dark Heart, Anthem, and Four 20 Pharma; U.S. dispensary activity; medical cannabis distribution in Germany and other international markets; share repurchase activity; board and shareholder matters; and regulatory topics affecting cannabis operations.
Curaleaf (OTCQX: CURLF) has formally launched its previously announced take-over bid to acquire all outstanding common shares of Aurora Cannabis. The Offer provides total implied consideration of US$4.00 per Aurora share, consisting of 0.3463 Curaleaf shares plus US$0.75 in cash, based on Curaleaf’s August 10, 2026 closing price of US$9.39.
The Offer represents a 45% premium to Aurora’s 30‑day VWAP unaffected share price of US$2.75 and a 110% ex‑cash premium. Consideration is capped at US$5.00 per share, with an exchange-ratio adjustment if Curaleaf’s 20‑day VWAP exceeds the defined cap price. The bid expires at 5:00 p.m. MT on December 1, 2026, unless extended, and is not subject to financing or due‑diligence conditions, only customary regulatory and other conditions.
According to Curaleaf, the combined company would have over US$1.5 billion LTM revenue, nearly US$350 million LTM adjusted EBITDA, a pro forma market capitalization above US$3.0 billion, and at least US$40 million of identified annual cost synergies.
Curaleaf (TSX:CURA, OTCQX:CURLF) announced its intention to launch a take‑over bid for all common shares of Aurora Cannabis (NASDAQ:ACB, TSX:ACB). The proposed consideration totals an implied US$4.00 per Aurora share, comprising 0.3463 Curaleaf subordinate voting share plus US$0.75 in cash.
According to Curaleaf, this reflects a 45% premium to Aurora’s 30‑day VWAP, or 110% excluding Aurora’s cash. If Curaleaf’s share price rises substantially before take‑up, total consideration per Aurora share would be capped at US$5.00, based on a 20‑day VWAP, which Curaleaf says would represent premiums of 82% and 197%, respectively.
Curaleaf has not yet formally commenced the bid and states there is no assurance the Offer will be made. The company highlights potential annual cost synergies of at least US$40 million, last‑twelve‑months pro forma revenue of over US$1.5 billion and nearly US$350 million in Adjusted EBITDA, and a pro forma market capitalization approaching US$3.0 billion for the combined entity. The Offer would not be subject to financing or due diligence conditions but remains contingent on multiple factors, including Curaleaf’s decision to proceed and potential defensive measures or alternative structures.
Curaleaf (TSX: CURA, OTCQX: CURLF) reported second quarter 2026 net revenue of $340.1 million, up 10% year-over-year and 5% sequentially. Domestic revenue was $288.7 million and international revenue $51.4 million. Gross profit reached $169.9 million with a 50% gross margin, up 70 basis points year-over-year.
Net income from continuing operations attributable to Curaleaf was $12.5 million, or $0.05 per share. Adjusted EBITDA was $70.1 million, with a 20.6% margin, down 120 basis points year-over-year. For the first half of 2026, net revenue was $664.3 million (+8% year-over-year) and gross profit $327.2 million (49% margin). The company ended the quarter with $107.0 million in cash and $611.5 million of outstanding debt, invested $32.9 million in capex, and repurchased 1.01 million shares for $7.4 million. Operationally, Curaleaf expanded its Florida retail footprint, launched its Dark Heart brand in 11 states, completed the buyout of the remaining 45% of Four20 Pharma, and noted post-quarter approvals for two cannabis medicines in Spain.
Curaleaf (OTCQX: CURLF, TSX: CURA) announced the opening of a new medical cannabis dispensary in Boynton Beach, Florida, located at 3575 W. Boynton Beach Blvd., on Friday, July 31. The store marks Curaleaf’s 75th Florida dispensary and brings its total U.S. retail footprint to 167 locations.
Situated in Palm Beach County near Boynton Beach Mall, the location offers a wide range of Curaleaf brands, including Anthem pre-rolls, Dark Heart ultra-premium flower, Grassroots premium flower, Select Live Collection, Select Briq 2 all-in-one vape, and Reef flower. A grand opening event is scheduled for July 31 and August 1 with in-store promotions, local gift card giveaways, and free swag. Store hours are 9:00 A.M.–8:30 P.M. ET Monday–Saturday and 10:00 A.M.–6:00 P.M. ET on Sunday.
Curaleaf (OTCQX: CURLF) announced the opening of a new medical cannabis dispensary in Edgewater, Florida, at 2115 S Ridgewood Ave on July 17, 2026. This store increases Curaleaf's Florida footprint to 74 dispensaries and its total U.S. retail locations to 166. The Edgewater site offers multiple Curaleaf brands and product formats and will host a grand opening event July 24–25, with regular operating hours set for seven days a week.
Curaleaf (OTCQX: CURLF, TSX: CURA) announced that Spain's Agency of Medicines and Medical Devices (AEMPS) has formally approved the registration of two standardized cannabis preparations, THC-dominant and CBD-dominant, developed by its Spanish manufacturing subsidiary. These registrations enable supply to hospital pharmacies for use in magistral formulas under medical prescription.
According to Curaleaf, the products received registry numbers CAN-1 and CAN-2, making the company the first to register standardized cannabis preparations in Spain under Royal Decree 903/2025, which defines the national framework for medicinal use of standardized cannabis preparations. The milestone builds on Curaleaf's EU-GMP certified manufacturing and R&D facility in Alicante and Medalchemy SL's 2020 AEMPS license to process medicinal cannabis derivatives for commercial distribution.
Curaleaf (OTCQX: CURLF, TSX: CURA) announced that exchange-traded options on its subordinate voting shares are expected to begin trading on the Montréal Exchange on July 13, 2026 under the symbol CURA. The listing decision was made independently by the exchange based on its eligibility criteria.
According to Curaleaf, MX-listed options may broaden investor tools for hedging, income and directional strategies, and could help enhance liquidity and price discovery. The options are contracts between market participants, involve no new share issuance, create no dilution, and generate no proceeds for the company. No shareholder action is required.
Curaleaf (OTCQX:CURLF, TSX:CURA) announced that, effective July 6, 2026, its Subordinate Voting Shares have resumed trading on the OTCQX Best Market under the symbol CURLF.
The change follows a 20-trading-day transition period under CURLD after a 1-for-3 reverse stock split. No shareholder action is required.
Curaleaf (OTCQX:CURLF, TSX:CURA) will report second quarter 2026 financial and operational results for the period ended June 30, 2026, after market close on August 5, 2026.
Management will host an earnings conference call and webcast at 5:00 p.m. ET, including prepared remarks and a Q&A session.
Curaleaf (OTCQX:CURLF) held its 2026 annual and special shareholders meeting via webcast on June 22, 2026, with 1,712,387,752 votes cast. Shareholders approved an amendment removing the automatic conversion feature of multiple voting shares, an option exchange program for up to 10,070,478 options, and a plan of arrangement to continue the company from British Columbia to Delaware. The amendment and arrangement received approval levels up to 100% within certain share classes, and all seven board nominees were elected with at least 97.156% support.